LGVNLongeveron Inc.

$18M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+163.7% YoY

Gross Profit

$2M32.4% margin

Operating Income

-$4M-67.1% margin

Net Income

-$4M-66.1% margin

EPS (Diluted)

$-1.87

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$136,846

Balance Sheet

Total Assets

$11M

Total Liabilities

$6M

Stockholders' Equity

$4M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+163.7%
Gross Profit	$2M	$680,649	+168.3%
Operating Income	-$4M	-$6M	+40.6%
Net Income	-$4M	-$6M	+41.3%

LGVN FY 2019 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena